Preclinical Rheumatoid Arthritis: Pipeline Analysis & Biomarker Insight, H1 2018.

Scope of report

• The report provides brief overview of Preclinical RA.
• This report discusses ‘risk factors for development of RA’ and ‘at risk population’.
• This report provides comparison of ‘at risk population’ and ‘classified RA patients’ based on biomarker analysis.
• This report discusses lessons learned from animal studies
• This report elaborates biomarker insight from retrospective human studies
• The report covers clinical therapeutics in development for preclinical RA including product profiles, trial summaries.
• The report mentions rational of clinical trial designs and insight from clinical trials.
• The report elaborates Potential methodologies for investigating preclinical RA.
• The report features clinical Pipeline insight based on MOA, sponsor & route of administration
• The report also covers preclinical pipeline insight.
• The report captures recent news and collaborations in development of therapeutics for preclinical RA

Reasons to buy

• The report provides brief overview of Preclinical RA.
• The report provides a snapshot of the global therapeutic landscape of Preclinical RA.
• The report assesses Preclinical RA pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA) and route of administration (RoA).
• The report reviews Preclinical RA pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The report covers pipeline products based on various stages of development for Preclinical RA ranging from discovery to pre-registration and undisclosed stages.
• The report features descriptive drug profiles for the pipeline products which includes, product briefs, MoA description, rationale of development, clinical trial details with results if published, partnerships activity & current status.

Companies covered

Bristol-Myers Squibb, Johnson & Johnson, Padlock Therapeutics, Cell Therapeutics, ModiQuest Research,

Key Drugs

Abatacept, Hydroxychloroquine, Rituximab, Methotrexate, Atorvastatin

Publisher: Pharmintel

Format: Microsoft word/PDF

Pages: 47

Price:

• Single Use: $1000
• Site License: $1500
• Global License: $2000